Roche’s Weak Earnings Add Fuel To Merger Fire
This article was originally published in The Pink Sheet Daily
Executive Summary
Poor financial performance highlights the Swiss pharma’s need to own Genentech outright.
You may also be interested in...
How Sweet It Isn’t: Genentech Investors Want Higher Roche Bid
New survey suggests Genentech’s minority shareholders won’t tender at the $86.50 price.
How Sweet It Isn’t: Genentech Investors Want Higher Roche Bid
New survey suggests Genentech’s minority shareholders won’t tender at the $86.50 price.
Roche Ups Negotiating Ante With Hostile Bid For Genentech
By making a hostile bid for Genentech at a lower price, Roche is trying to address at least two important concerns in one blow: uncertainty over upcoming results of a key clinical trial for the blockbuster Avastin cancer medication and offsetting potentially higher financing costs needed to ink the deal due to the troubled economic climate